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Letters to the Editor
Keratin 19 mRNA is detectable by RT-PCR in lymph
nodes of patients without breast cancer
Sir
We were interested to read the paper on the use of cytokeratin 19
(K19) mRNA by reverse transcription polymerse chain reaction
(RT- PCR) combined with Southern blotting for the detection of
lymph node micrometastasis in breast cancer patients by
Schoenfeld et al (1996). The authors have reported that, among 75
histologically node-negative breast cancer patients, 23 (30.6%)
demonstrate K19 mRNA in their lymph nodes whereas none of 28
control lymph nodes without epithelial malignancy show K19
expression.
This report and another by Traweek et al (1993) are in sharp
contrast with our data in that K19 mRNA is readily detected by
RT-PCR in 31 of 40 (77.5%) lymph nodes from five of eight
patients with benign bowel diseases, none ofwhom had any signs
of an epithelial malignancy. We also found that two of these same
eight had K19-positive bone marrow aspirates. Our methods
involve extremely careful dissection of lymph nodes before
cutting any epithelial tissue to avoid epithelial cell contamination
from surgical gloves or dissection equipment. RNA extractions
were performed, including blank samples, so that reagent contam-
ination could not account for positive results. Our PCR strategy
allows discrimination of K19 cDNA-derived PCR products from
K19 genomic DNA- or K19 pseudogene-derived PCR products,
methodologies of which have recently been published by Gunn et
al (1996). Furthermore, we showed that the 31 lymph nodes that
expressed K19 mRNA did not express keratin 20, a gene
expressed highly by the epithelial cells ofthe gastrointestinal tract
only) ruling out epithelial cell contamination as the source of K19
mRNA in these lymph nodes. Among 35 breast cancer patients so
far studied, 17 were histologically node negative whereas 18 were
histologically node positive. Ninety-five of 143 lymph nodes
(66.4%) from the former group and 128 of 166 lymph nodes
(77.1%) from the latter group were found to be K19 positive by
RT-PCR. From these findings we have concluded that a low level
of K19 mRNA is expressed in most lymph nodes, and that these
data concur with previous reports by Krisman et al (1995), Adams
et al (1995) and Burchill et al (1995).
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Keratin 19 mRNA is detectable by RT-PCR in lymph
nodes of patients without breast cancer - reply
Sir
We agree that K19 mRNA is detectable in normal lymph nodes
(from patients without any epithelial malignancy) by reverse tran-
scription polymerase chain reaction (RT-PCR) after many cycles
of amplification. In our paper (Schoenfeld et al, 1994), we
described the methodology and demonstrated a 'cut-off' of 40
cycles of amplification beneath which all normal lymph nodes
remained negative for K19 mRNA; those above this level may be
taken to indicate lymph node metastases. In our studies, this 'cut-
off' occurred after40cycles ofRT-PCR and Southern hybridization.
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A second amplification, using nested primers, resulted in the
appearance of mRNA-derived K19 product in normal nodes as
well as nodes from cancer patients. Thus, there is a low level of
K19 mRNA in normal nodes, and the potential of RT-PCR in the
staging of breast cancer is therefore limited by the specificity of
the tumour marker.
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Mutations at codon 974 of the DPYD gene are a rare
event
Sir
We regret to inform you of an error made in a recently published
article in the British Journal of Cancer (75: 178-179). 'Mutations
at codon 974 ofthe DPYD gene are -a rare event' from Ridge et al
(1997). In this study, Ridge et al attempted to determine the
frequency of a mutation originally described by our laboratory in
1995 (abstract presented at the American Association of Cancer
Research, AACR). Unfortunately, the authors of this study misin-
terpreted the position ofthe mutation [A (control) to T (mutation)]
originally localized at position 2921 in the open reading frame of
dihydropyrimidine dehydrogenase cDNA. When translated, this
mutation results in an Asp to Val substitution corresponding to
codon 949, not to codon 974 as reported by Ridge et al. The posi-
tion ofthe mutation reported in the AACR abstract was based on a
complete human DPD cDNA amplified using primers designed
against bovine liver cDNA (Figure 1). Both the original
numbering system and the codon number (949) were presented at
the 1995 AACR meeting (Albin N et al (1995) Proc Am Assoc
CancerRes 36: 211).
After a careful review of this article, we have determined that
Ridge et al assigned the first adenosine nucleotide in the initiating
methionine as the number 1 position. This resulted in the incorrect
assignment ofcodon 974 as the site ofthe mutation (Figure 1). We
concur with Ridge et al that the frequency ofthis mutation should
be determined in the population and will therefore forward a copy
of this letter to Ridge et al, along with an offer to provide any
information necessary to correct this study.
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1 Bovine primer 1
5' ACTTTCGTCTCTGGCTGAAGCCTGAGGACGCAAGGAGGGTTlGTCACTGGCAGACTCGAGACTGTAGGCACTGCC ATG... 3'
Met
Original numbering system T
used in the 1995 AACR abstract Ridge et al (1997)
Figure 1 The bovine primer (bold and underlined) used to PCR amplify the 5' end of human lymphocyte DPD cDNA. The original numbering system assigned
the 5' end of the bovine primer as the number 1 position, with the mutation ultimately corresponding to position 2921, as originally presented in the abstract.
Ridge et al (1997) assigned the first adenosine nucleotide in the initiating methionine as the number 1 position and therefore localized the mutation to the wrong
codon (974 instead of 949)
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